Advaxis to Present Updated Clinical and Immunogenicity Data

Overall response rate of 14% and disease control rate of 36% in Part B of ADXS-503 trial with durable clinical benefit as an add-on therapy to patients...

Related Keywords

United States , New Jersey , American , , American Society Of Clinical Oncology , Advaxis Inc , Present Updated Clinical , Immunogenicity Data , Ongoing Phase , Metastatic Non Small Cell Lung Cancer , Study Design , Early Prostate Cancer , American Society , Clinical Oncology , Other Otc Adxs , Advaxis , Nc ,